• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 3, 2017

View Archived Issues

Time Lords and Night Owls: Nobel goes for circadian rhythm work

Living in Stockholm, where the length of daylight ranges from about six hours at winter solstice to 18.5 hours at midsummer, pretty much guarantees a curiosity about how internal circadian rhythms are maintained. Read More

Regulatory front

The FDA is seeking comment on the design of its REMS Platform Standards Initiative, as well as the methods and best practices for its construction. Read More

In the clinic

Innovation Pharmaceuticals Inc., of Beverly, Mass., said the last patient completed study treatment in its phase II trial of brilacidin for the prevention and treatment of severe oral mucositis (OM) in patients undergoing chemoradiation for head and neck cancer. Read More

Financings

Arbutus Biopharma Corp., of Vancouver, British Columbia, said it signed a share purchase agreement with Roivant Sciences Inc., of New York, for the sale of convertible preferred shares for gross proceeds of $116.4 million, which the company intends to use to further develop and advance its clinical and preclinical hepatitis B virus (HBV) pipeline programs. Read More

Third quarter ends with a bang, not a whimper: European biotechs raise $837M

DUBLIN – A flurry of deals in late September added a burst of energy to what was otherwise a pretty sleepy third quarter for European biotech firms engaged in drug development. The last week of the month – and of the quarter – was a particularly busy one. European firms raised $472 million during that time, more than half of the total third-quarter raise, which came to $837 million. Read More

'A complete game-changer' as Ablynx's caplacizumab scores in phase III aTTP trial

LONDON – Shares in Ablynx NV rose by 25.8 percent on Monday to €15.50 (US$18.20) when the company announced positive results from the phase III study of caplacizumab in the treatment of rare blood coagulation disorder acquired thrombotic thrombocytopenic purpura (aTTP). Read More

Biohaven's trigriluzole falls short in phase II/III ataxia trial

Biohaven Pharmaceutical Holding Co. Ltd.'s trigriluzole, the most advanced candidate from its glutamate modulation platform, failed to outperform a placebo in the treatment of spinocerebellar ataxia (SCA) during a phase II/III study, the largest trial conducted in the rare disorder to date. Read More

Crisper CRISPR? KSQ emerges with $76M to prove its mettle in gene play

Looking to one-up early stage entries in harnessing CRISPR technology, 2-year-old KSQ Therapeutics burst onto the biopharma scene with $76 million across two financing rounds and an aspiration to pioneer what it called "high-confidence" drug development. Read More

Drug prices at heart of generics guidances, FDA workshop

Making good on Commissioner Scott Gottlieb's promise to tackle high drug prices by streamlining the path for generics, the FDA issued new guidance on developing generics of complex drugs and opened a two-day workshop Monday on ways to modernize the development and review of generic drugs. Read More

TGA report card: On-time drug, device reviews, better access to unapproved drugs

PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) reported a mixed review for its annual performance for drugs and devices covering the period from July 2016 to June 2017 compared to the previous year. Read More

Other news to note

Opiant Pharmaceuticals Inc., of Santa Monica, Calif., and Titan Pharmaceuticals Inc., of South San Francisco, are collaborating to develop a product for the prevention of opioid relapse and overdose in individuals with opioid use disorder using Titan's Proneura sustained-release technology. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe